To print: Select File and then Print from your browser's menu

Title: Intrathecal Methotrexate Results In Greater Systemic Exposure In Children

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12571461&dopt=Abstract

J Pediatr Hematol Oncol 2003 Feb;25:2:114-7. "Systemic methotrexate exposure is greater after intrathecal than after oral administration."
03/06/2003 09:45:40 AM
By Elda Hauschildt

Systemic methotrexate exposure in paediatric patients is significantly greater after intrathecal administration than oral administration, say investigators from the United States. Intrathecal dosing of methotrexate resulted in an average systemic exposure of 1.7 to 1 compared with oral administration, report the researchers, led by Dr. Bruce Bostrom from Children's Hospitals and Clinics in Minneapolis, Minnesota. Red cell methotrexate polyglutamate concentrations were analysed in 80 children enrolled in a Children's Cancer Group trial for acute lymphoblastic leukaemia. Patients were used as their own controls. Intrathecal methotrexate was prescribed on an age-adjusted schedule. Methotrexate concentrations were measured seven days after the last doses of both intrathecal and oral administration. Mean red cell methotrexate concentration was 178 pmol/mL red blood cells after the last of four weekly doses of intrathecal administration, the investigators found. This was significantly greater than the 122 pmol/mL results seven days following subsequent oral administration.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12571461&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.